Symptom experience of patients with thyroid-associated ophthalmopathy during treatment with tiutumumab infusion.
Conditions
Interventions
Observation group:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.diagnosed as thyroid associated ophthalmopathy; 2. age>=18 years old; 3.patients who were treated with tiumumab; 4.clear consciousness, normal comprehension and expression; 5. Informed consent and active participation in this study.
Exclusion criteria
Exclusion criteria: 1.Complicated with other ophthalmic diseases; 2.Within 3 months after receiving other treatment regimens (e.g., orbital decompression surgery, orbital radiotherapy, cumulative methylprednisolone dose>=1g, rituximab or tocilizumab treatment); 3.History of other diseases: history of hemorrhagic diseases, history of malignant tumors within the past year, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Burden of symptoms; | — |
Countries
China
Contacts
Public ContactLuo Hongmei
West China Hospital of Sichuan University
Outcome results
None listed